Moximed Announces Appointment of Dave Amerson to Board of Directors

• Amerson has demonstrated commercial leadership of multiple early-stage medical device technologies with nearly $3 billion in transaction value for investors

FREMONT, Calif.--(BUSINESS WIRE)-- Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that Dave Amerson has joined the company’s Board of Directors.

“Dave has established an unrivaled track record of successful commercialization of new medical device technologies,” said Anton Clifford, Ph.D., founder and CEO of Moximed. “His unique perspective and experience bringing game-changing med-tech solutions to market are timely additions to our Board as we accelerate our commercialization of the MISHA™ Knee System in the United States. We are excited to welcome him to our Board.”

“I am thrilled to join Moximed’s Board of Directors at this exciting point in the company’s commercial trajectory,” said Mr. Amerson. “The parallels I see between Moximed and my experience successfully leading and advising other disruptive med-tech companies is compelling. Moximed has developed a unique, patient-centered solution to a massive clinical problem. The company reports excellent clinical outcomes, has FDA market authorization, and is now seeing tremendous surgeon and patient interest in the MISHA Knee System. I’m excited to work with Anton and the team to help more patients gain access to the technology and to similarly contribute to Moximed’s future success.”

Amerson has over three decades of leadership experience and nearly $3 billion of M&A transactions in medical devices as a CEO or as an active board member. Amerson served as President and Chief Executive Officer of NeoTract, Inc., which was acquired by Teleflex in 2017 in a transaction valued at up to $1.1 billion. In addition, Amerson served on the Board of Directors for Relievant Medsytems, Inc., which was acquired by Boston Scientific Corporation in 2023 for an upfront cash payment of $850 million and undisclosed additional payments based on commercial milestones. He also served as Chairman of the Board of Palette Life Sciences, which was acquired by Teleflex in 2023 for an upfront cash payment of $600 million and an additional $50 million based on certain milestones.

Amerson joins Josh Makower (Chairman), Anton Clifford, Arthur Franken, Shahzad Malik, Matt McAviney, Hank Plain, Kevin Sidow, Brigitte Smith, and David van Meter on Moximed’s Board of Directors.

About The MISHA™ Knee System

Moximed’s MISHA Knee System is for people with medial knee OA who failed to find relief from previous treatments. These patients continue to experience pain that interferes with daily activities, and are ineligible for, or unwilling to undergo, joint replacement due to age or absence of advanced OA.

Knee OA develops when the joint’s natural shock absorbers, cartilage and meniscus, no longer cushion the joint from daily activities, leading to chronic pain and activity limitation. Many people with mild to moderate OA are otherwise healthy, in their prime working years, and have busy lives. For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease. OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life.

Reducing weight on painful osteoarthritic joints is known to reduce pain and improve function. The MISHA Knee System is the first implantable shock absorber that reduces weight on the knee joint with every walking step, easing pain, preserving function, and possibly delaying joint replacement surgery. The implant is placed on the medial knee and moves with the natural joint, reducing about 30% of the peak force on the knee with every walking step.ⁱ

The MISHA Knee System is FDA cleared.

About Moximed

Moximed’s technology, the MISHA Knee System, is the result of over a decade of clinical research and development and is the first implantable shock absorber for the treatment of medial compartment knee osteoarthritis (OA). With experienced med-tech leadership and strong investor support, Moximed is poised to elevate the standard of care and quality of life for millions of pre-arthroplasty knee OA sufferers hindered by arthritic knee pain and function loss. Moximed is based in Fremont, California.

To learn more, visit www.moximed.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240104305465/en/